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Unfortunately, the original version of this article \[[@CR1]\] contained an error. Figures [2](#Fig2){ref-type="fig"} and [7](#Fig7){ref-type="fig"} were the incorrect versions. They have been corrected in the original article and are also included correctly in this erratum.Fig. 2Development of LIVP-GFP infection in various tumour cells. Development of LIVP-GFP infection in RLS (*green circles*), RLS-40 (*red circles*), KB-3-1 (*violet squares*), KB-8-5 (*black line with open squares*) and melanoma B-16 (*blue triangles*) tumour cells at MOI of 1 (**a**) and MOI of 10 (**b**). Cells were incubated with virus for 1 h, washed with PBS and incubated up to the analysis in IMDM supplemented with 2 % FBS. Viral titre was measured by PFU assay. Data of three independent experiments are presentedFig. 7Effect of LIVP-GFP treatment on the immune responses of tumour-bearing mice. **a** Summary data showing a significant increase of the number of IFN-γ-ransecreting splenocytes in LIVP-GFP-treated mice (n = 6) with RLS-40 or with melanoma B-16 tumours. Comparison of immune-related proteins GMC-SF (**b**) and IL-6 (**c**) in the blood serum of RLS-40 bearing mice during the treatment with LIVP-GFP (the experimental scheme was shown in Fig. 5a): *red circles* and *blue squares* for RLS-40 bearing mice treated with LIVP-GFP and PBS, respectively; *black triangles* healthy mice receiving PBS. The levels of cytokines in the blood serum were measured by ELISA. For each day, the value of mean ± SEM is shown

The online version of the original article can be found under doi:10.1186/s12967-016-1002-x.
